Economic Impact of Using Additional Diagnostic Tests to Better Select Patients With Stroke for Intravenous Thrombolysis in the United Kingdom

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1544-1558

  Earnshaw, Stephanie R ^a   McDade, Cheryl ^a   Chapman, Ann Marie ^b   Jackson, Daniel ^c   Schwamm, Lee ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b GE HEALTHCARE   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Computed tomography perfusion imaging; Cost effectiveness; Diagnostics; Magnetic resonance imaging; Stroke

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC TEST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; QUALITY ADJUSTED LIFE YEAR; RANKIN SCALE; STROKE PATIENT; UNITED KINGDOM;

AGED; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PATIENT SELECTION; PERFUSION IMAGING; QUALITY-ADJUSTED LIFE YEARS; STROKE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863825822     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.05.004     Document Type: Article

References (39)

1. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363:768-774. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators.
2. Lees K.R., Bluhmke E., von Kummer R., et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703. ECASS, ATLANTIS, NINDS, and EPITHET rt-PA Study Group.
3. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329. ECASS Investigators.
4. Lansberg M.G., Bluhmki E., Thijs V.N. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischaemic stroke. Stroke 2009, 40:2438-2441.
5. National Clinical Guidelines for Stroke 2004, Intercollegiate Stroke Working Party, Intercollegiate Stroke Working Party, London, United Kingdom. 2nd ed.
6. Actilyse [summary of product characteristics] 2009, Boehringer Ingelheim Ltd, Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
7. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 European Stroke Organisation [ESO] Executive Committee and the ESO Writing Committee, Accessed September 27, 2010. http://eso-stroke.org.
8. Adams H.P., del Zoppo G., Alberts M.J., et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38:1655-1711. American Heart Association, American Stroke Association Stroke CouncilAmerican Stroke Association Stroke Council, Clinical Cardiology CouncilClinical Cardiology Council, Cardiovascular Radiology and Intervention CouncilCardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working GroupsAtherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups.
9. Thomalla G., Schwark C., Sobesky J., et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006, 37:852-858. MRI in Acute Stroke Study Group of the German Competence Network Stroke.
10. Schellinger P.D., Thomalla G., Fiehler J., et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007, 38:2640-2645.
11. Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA) National Institute for Health and Clinical Excellence, Accessed July 30, 2012. http://www.nice.org.uk/CG068.
12. National stroke strategy Department of Health, Accessed June 4, 2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081062.
13. Wintermark M., Flanders A.E., Velthuis B., et al. Perfusion-CT assessment of infarct core and penumbra receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006, 37:979-985.
14. Earnshaw S.R., Jackson D., Farkouh R., Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke 2009, 40:1710-1720.
15. Jackson D., Earnshaw S.R., Farkouh R., Schwamm L. Cost-effectiveness of CT perfusion for selectin patients for intravenous thrombolysis: a US hospital perspective. Am J Neuroradiol 2010, 31:1669-1674.
16. Samsa G.P., Reutter R.A., Parmigiani G., et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999, 52:259-271.
17. Guide to the methods of technology appraisal National Institute for Health and Clinical Excellence, Accessed July 23, 2010. http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jsp.
18. Darby D.G., Barber P.A., Gerraty R.P., et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999, 30:2043-2052.
19. Albers G.W., Thijs V.N., Wechsler L., et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006, 60:508-517. DEFUSE Investigators.
20. Implementing the National Stroke Strategy-an imaging guide Department of Health, Accessed June 4, 2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085146.
21. Hand P.J., Wardlaw J.M., Rowat A.M., et al. Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient related difficulties. J Neurol Neurosurg Psychiatry 2005, 76:1525-1527.
22. Visipaque (iodixanol) injection [package insert] 2008, GE Healthcare Inc, GE Healthcare Inc, Princeton, NJ.
23. Cochran S.T., Bomyea K., Sayre J.W. Trends in adverse events after IV administration of contrast media. Am J Roentgenol 2001, 176:1385-1388.
24. Morcos S.K. Acute serious and fatal reaction to contrast media: our current understanding. Br J Radiol 2005, 78:686-693.
25. Katzan I.L., Hammer M.D., Hixson E.D., et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004, 61:346-350. Cleveland Clinic Health System Stroke Quality Improvement Team.
26. Harraf F., Sharma A.K., Brown M.M., et al. A multicentre observational study of presentation and early assessment of acute stroke. BMJ 2002, 325:17.
27. Wintermark M., Reichhart M., Cuisenaire O., et al. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 2002, 33:2025-2031.
28. Curtis L. Unit costs of health and social care Accessed July 13, 2010. http://www.pssru.ac.uk/pdf/uc/uc2009/uc2009.pdf.
29. National Sentinel Stroke Audit Phase II (Clinical Audit) 2008: Report for England, Wales and Northern Ireland 2009, Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, London, United Kingdom.
30. National schedule of reference costs 2008-09 for NHS Trusts Office for National Statistics, Accessed July 22, 2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publication/PublicationsPolicyAndGuidance/DH_111591.
31. Impact Assessment: National Stroke Strategy 2007, Stroke Team, Department of Health, National Health Service, National Health Service, Preston, United Kingdom.
32. Reed S.D., Blough D.K., Meyer K., Jarvik J.G. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001, 57:305-314.
33. British National Formulary 2010, British Medical Association and Royal Pharmaceutical Society of Great Britain, Royal Pharmaceutical Society of Great Britain, London, United Kingdom. 59th ed.
34. Kleindorfer D., Hill M.D., Woo D., et al. A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke 2005, 36:682-687.
35. Dorman P., Dennis M., Sandercock P. Are the modified "simple questions" a valid and reliable measure of health related quality of life after stroke?. United Kingdom Collaborators in the International Stroke Trial. J Neurol Neurosurg Psychiatry 2000, 69:487-493.
36. McGuire A.J., Raikou M., Whittle I., Christensen M.C. Long-term mortality, morbidity, and hospital care following intracerebral hemorrhage: an 11-year cohort study. Cerebrovasc Dis 2007, 23:221-228.
37. Interim life tables, United Kingdom, 1980-82 to 2006-08 Office for National Statistics, Accessed July 2, 2010. http://www.ons.gov.uk/ons/datasets-and-tables/index.html.
38. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000, 17:479-500.
39. Nagakane Y., Christensen S., Brekenfeld, et al. EPITHET positive results after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke 2011, 42:59-64.